Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Porsolt

Porsolt

Porsolt is a global CRO based in France.We provide a broad range of contract services for non-clinical development, ranging from early drug discovery screening to pharmacology, safety evaluation, pharmacokinetics, and support toward regulatory submissions.The tests are conducted not by an agency, but by our own research facility and specialized staff.

Characteristics of Porsolt's non-clinical contract testing services

Efficacy evaluation and pharmacological testing for diverse disease areas

In Porsolt,Central nervous system, cardiovascular, inflammation, oncology, pain, respiratory, liver disease, metabolic disease, skin disease, etc.We support non-clinical research across a wide range of fields. Equipped with various evaluation systems including in vitro, ex vivo, in ovo, and in vivo, we conduct pharmacological studies using multiple animal species. We can develop testing systems tailored to your research objectives, ranging from early-stage drug discovery screening to the efficacy evaluation of candidate compounds.

Safety pharmacology and non-clinical studies compliant with GLP

In the safety evaluation,Pharmacological and toxicological tests compliant with GLPare being conducted. We support studies evaluating effects on the cardiovascular, central nervous, and respiratory systems as a core battery based on ICH S7. A wide range of evaluations from in vitro to in vivo is possible, including hERG channel assays, blood pressure, heart rate, and electrocardiogram measurements, as well as respiratory function evaluations. Porsolt has continuously maintained its GLP compliance status since passing a GLP compliance audit in 2000.

Supporting drug discovery and development from pharmacokinetics to regulatory submissions

Not only efficacy evaluation,pharmacokinetic study, formulation analysis, bioanalysis, toxicity evaluationWe also offer services such as pharmacokinetics using multiple animal species including mice, rats, dogs, and minipigs, with the capability to collect samples of blood, plasma, cerebrospinal fluid, and various tissues. In addition, we provide scientific support for regulatory submissions at each stage of non-clinical development.

Source: Porsolt official website
https://www.porsolt.com/

An example of a disease model owned by Porsolt

At Porsolt, we have developed various in vivo and in vitro models for each disease area. For example, in the oncology field,orthotopic and subcutaneous xenograft models targeting breast cancer, lung cancer, colorectal cancer, glioblastoma, etc.Supports drug efficacy evaluation using [X]. Models can be selected according to the disease and evaluation purpose.

Source: Porsolt official website
https://www.porsolt.com/

Porsolt preclinical study cases

Predictive toxicity evaluation using 2D and 3D models

The Porsolt official website publishes papers and research results related to non-clinical research. For example,A study continuously evaluating drug withdrawal in rats using telemetryNow, we are measuring body temperature, amount of exercise, heart rate, mean arterial pressure, and other parameters over time. On the other hand, case studies summarizing the contents and results of trials commissioned by individual pharmaceutical companies are limited on our official website.

Source: Porsolt Official Document: In Vitro Predictive Toxicity Screening Assays during Early Stage Drug Development: Case Study Data for the Validity of 2D and 3D Models
https://www.porsolt.com/wp-content/uploads/2023/Catalog/catalog_interactive_Porsolt.pdf

Porsolt's corporate information

Source: Porsolt official website
https://www.porsolt.com/
AddressZ.A. de Glatigné, 53940 Le Genest-Saint-Isle, France
Tel+33 2 43 69 36 07
Websitehttps://www.porsolt.com/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services